Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2015

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    WS08 - Joint IASLC-CSCO-CAALC Session: Liquid Biopsy in Oncogene Driven NSCLC (On-demand)

    • 21:00 - 23:59
    • 8/06/2022
    • Location: On-Demand
    • Not for CME Credit
    • Type: Workshop
    • Track: N/A
    • +

      WS08.11 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis

      22:50 - 23:00  |  Presenter: Yun Fan

      • Abstract

      This abstract is currently under embargo and will be released during the conference.

  • +

    EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      EP08.02-016 - Frontline and Post-Osimertinib Therapy for EGFR-mutant Advanced NSCLC: Treatment Patterns, Outcomes, Healthcare Use and Costs

      Presenter: Benjamin Besse

      • Abstract

      Loading...

    • +

      EP08.02-019 - Phase 1/2 Study of BLU-701, a Highly Selective EGFR Inhibitor, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

      Presenter: Alexander Spira

      • Abstract

      Loading...

    • +

      EP08.02-045 - Phase 1/2 Study of BLU-945 in Patients With Common Activating EGFR-Mutant Non-Small Cell Lung Cancer

      Presenter: Elaine Shum

      • Abstract

      Loading...

    • +

      EP08.02-113 - Clinico-genomic Characteristics of Patients with Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

      Presenter: Masanobu Okahisa

      • Abstract

      Loading...

    • +

      EP08.02-173 - Treatment Patterns and Outcomes Among Patients With EGFR-mutant Advanced NSCLC in the Frontline and Post-Osimertinib Settings

      Presenter: Joshua Sabari

      • Abstract

      Loading...

  • +

    MA13 - Update on ROS1 Inhibitors and New Pathways

    • 12:00 - 13:00
    • 8/09/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Mini Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
    • +

      MA13.04 - Entrectinib in Patients with ROS1 Fusion-Positive (ROS1-fp) NSCLC: Updated Efficacy and Safety Analysis

      12:07 - 12:12  |  Presenter: Yun Fan

      • Abstract

      Loading...